Creating an innovation ecosystem for rapid diagnostic tests for livestock to support sustainable antibiotic use

Creating an innovation ecosystem for rapid diagnostic tests for livestock to support sustainable antibiotic use
复制标题

DOI:
10.1080/09537325.2021.1950678
复制
发表时间:
2021-07-10
影响因子:
3.4
通讯作者:
Tait, Joyce
Tait, Joyce
中科院分区:
管理学4区
文献类型:
--
作者:
Bruce, Ann;Adam, Katherine E.;Tait, Joyce

文献摘要

被引文献

相似文献

抗生素耐药性 (AMR) 是当今最大的公共卫生威胁之一,减少牲畜中抗生素的使用对于防止其传播至关重要,需要快速诊断测试 (RDT) 以确保处方药物与疾病微生物的敏感性相匹配。然而,尽管对 RDT 进行了数十年的研究,并且英国的监管环境相对宽松,但很少有设备投入商业使用。 RDT 开发人员讨论的挑战包括确定商业上可行的目标以及创新生态系统的管理,例如创建清晰的市场路径,支持农民、兽医和价值链上其他参与者之间的积极互动。未来对 RDT 发展的支持可以通过纳入以下方面来提供: 有保障的粮食系统;中心实验室提供的业务服务包;或与抗菌素耐药性传播相关的动物健康监测包。种畜销售可能需要附带的健康包,包括 RDT、疫苗和/或抗生素,与精准农业方法相关。与针对 COVID-19 的 RDT 开发示例不同,问题的紧迫性以及动物与人类健康结果之间联系的清晰度似乎还不足以支持开发 RDT 来对抗 AMR 的快速跟踪计划。
Antimicrobial resistance (AMR) is one of today's greatest public health threats and reducing antimicrobial use in livestock is essential to prevent its spread, requiring rapid diagnostic tests (RDTs) to ensure that the drug prescribed matches the sensitivity of the disease organism. However, despite decades of research on RDTs and a relatively permissive regulatory environment in the UK, few devices are in commercial use. Challenges discussed by RDT developers included identifying commercially-viable targets, and management of the innovation ecosystem, e.g. to create clear pathways to market supporting positive interactions between farmers, vets, and other actors along the value chain. Future support for RDT development could be provided through incorporation in: assured food systems; business service packages provided by centralised laboratories; or animal health monitoring packages related to the spread of AMR. Breeding stock sales could require an accompanying health package including RDTs, vaccines and/or antibiotics, linking to precision agriculture approaches. Unlike the example of RDT development for COVID-19, it seems that the urgency of the issue and the clarity of links between animal and human health outcomes are not yet sufficient to support a fast-tracking programme for the development of RDTs to combat AMR.